Background: Osteoarthritis (OA) is a chronic degenerative joint disease and is considered to
Biological therapies, including chondrocyte implantation, have shown some potential and established guidelines for future treatment back in early 1990s. 12 Tremendous advances in this field came with the utilization of stem cells. Several clinical trials were conducted to test the efficacy and potency of mesenchymal stem cells (MSCs) for the treatment of hip and knee osteoarthritis. 2, [13] [14] [15] [16] Physiological selfrepair of cartilage results in a fibrous cartilage that is biomechanically inferior to hyaline. Application of autologous MSCs grown in cell culture up to a certain therapeutic theshold results in the restoration of hyaline cartilage. 15 Stem cells represent unspecialized cells that have the ability to differentiate into different cell types. Mesenchymal stem cells are the most promising candidates for the treatment of cartilage defects because they show good differentiation potential towards cartilage and bone cells. They can be isolated from a number of adult mesenchymal tissues, such as trabecular bone, adipose tissue, bone marrow, synovium, dermis, periodontal ligament, dental pulp, bursa and the umbilical cord. 17 Adipose tissue is considered as a primary source because it contains 500 times more MSCs than the same volume of bone marrow 18 and sampling is performed via a minimally invasive surgical procedure, which is safe and cosmetically accepTable. 19 That is why adipose-derived (AD)-MSCs have come into focus for regenerative medicine.
In the present study, nine patients were treated using AD-MSCs.
In two patients, both knees were treated and so, in total, 11 knee joints were followed up. During follow-up, all the patients were evaluated clinically and using radiography and magnetic reonance imaging (MRI) visualization.
| MATERIALS AND METHODS

| Study design
The research was carried out in compliance with the Helsinki Declara- 20 We used the IKDC classification because of its reliability and good correlation with clinical and arthroscopic data. 21 Baseline patient data are listed in 
| Follow-up
During the follow-up period, patients were allowed to carry out their regular daily activities. Clinical and radiologic evaluation was conducted before treatment and at regular intervals (3, 6, 12 and 18 months). Common clinical scores were used for knee osteoarthritis:
KSS, 22 Hospital for Special Surgery knee score (HSS-KS) 23 and
Tegner-Lysholm (T-L) score. 24 Knee range of motion was measured using digital goniometer and level of pain was self-reported using a visual analogue scale (VAS). Radiographic data were collected from plain knee radiography in the standing position. MRI was performed before the intervention and after 6 and 18 months of follow-up, analyzed in the sagittal and axial planes, and assessed for markers of osteoarthritis (joint space narrowing between femur and tibia, intensity and distribution of subchondral sclerosis, presence of osteophytes or subchondral cysts), signs of inflammation and amount of joint fluid.
Analysis of radiographic images was performed using ImageJ 25 
| Potential towards osteogenic and chondrogenic differentiation
To determine differentiation potential of isolated MSCs, cells were induced to differentiate toward osteognenic and chondrogenic lineage. 3 | RESULTS
| Clinical outcomes
A few days after injection, some patients reported moderate pain and swelling of the knee. These symptoms vanished within 1 week after Table 2 and individual patient datasets are provided in the Supporting information (Table S1 ).
The first control visit was 3 months after injection. Figure 1 and Table 2 ).
At second visit, 6 months after injection, further significant improvement of all clinical parameters was observed. 
| Radiological parameters
Regarding plain radiological parameters, there were no significant changes (improvement or worsening) during the follow-up period compared to baseline. No formation of new osteophytes or cysts were seen, nor were there any changes in the amount of synovial fluid. Average change of subchondral sclerosis intensity before and at the end of follow-up was 0.41 ± 7.76%, with significant individual variations: in some cases, it increased by 9%, whereas, in others, it decreased by 15.6% (Figures 2A and 2D 
| MRI evaluation
On the other hand, MRI findings revealed structural cartilage enhancement in accordance with observed clinical results. Fewer subchondral cysts and oedema were visible on both femoral and tibial condyles, with more uniform cartilage signal being seen globally on T2 sequence ( Figures 2B and 2D ). Average 2D MOCART score before treatment was 43 ± 7.2 (maximum of 100) and, after 18 months, it was 63 ± 17.1 points, indicating an improvement with high statistical significance (Fischer's exact test, t = 0.970, p = 0.001) (Figure 3 ).
| MSC characteristics
Characterization of isolated cells showed phenotypic characteristics specific for mesenchymal stem cells according to the International Society for Cellular Therapy. 28 Characteristic fibroblast-like phenotype ( Figure 4A ), adherence to plastic surface, potential for differentiation into mesenchymal lineage cell types (chondrogenic and osteogenic), expression of certain mesenchymal surface markers (CD73, CD90
and CD105) and an absence of expression of hematopoietic surface markers (CD34 and CD45). Differential staining showed that isolated Figure 4C ).
| DISCUSSION
In the present study, we report our findings concerning the treatment of nine patents (11 knees, two patients treated bilaterally) with knee osteoarthritis using ex vivo expanded autologous AD-MSCs, with The findings reported by Davatchi et al. 13, 29 showed that the beneficial effect starts to decline after 6 months, although this is still better at 5 years compared to baseline. The study by Emadedin et al., 14 who had 1 year of follow-up, reported a duration of improvement over 6 months and, subsequently, the effects appeared to be slightly decreased. Using the bone marrow as a source of stem cells, as in both studies mentioned above, Orozco et al. 2 reported a duration of pain improvement at follow-up of 2 years after treatment. 2 Two studies that used AD-MSCs showed an improvement of all clinical and histological findings, although there were contradictory results concerning the dose of applied cells. 15, 16 The mahority the early improvements seen in most of the studies 
| Concluding remarks and future perspectives
The results obtained in the present study suggest that the injection of proposed dose of AD-MSCs may be a safe and efficient method of osteoarthritis treatment. This treatment has several advantages compared to other available treatments: it is minimally invasive, almost all joints can be treated and it is repeatable when needed. We consider that the present study provides a good basis for sound prospective randomized controlled clinical trials.
